DATA GRAPHICS | Data Byte
Safety readout dims prospects for AltImmune’s obesity therapy
GI effects suggest dual agonist could have trouble finding foothold in competitive area, even if treatment effect strengthens over time
March 21, 2023 9:56 PM UTC
Even if a longer duration of treatment with AltImmune’s GLP-1R/GCGR agonist pemvidutide generates efficacy data comparable to approved and clinical therapies, the safety and tolerability data available from 24 weeks of dosing suggest the therapy could have a hard time competing in a fast-evolving field.
As the the Phase II findings are the first from a dual agonist of GLP-1R and GCGR in obesity, they also raise questions about the tolerability of other GLP-1R, GCGR dual agonists. ...
BCIQ Company Profiles